BASi Research Products

BASi Research Products

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BASi Research Products, founded in 1974 and now a key product division of Inotiv (NOTV), has established itself as a leader in innovative preclinical research tools. Its mission is to empower drug discovery through technologies that automate and refine in vivo sampling, allowing researchers to obtain superior longitudinal data while reducing animal use and experimental variability. The company's strategy leverages its integration within Inotiv's full-service CRO to offer bundled product-service solutions, targeting growth within the expanding preclinical research market driven by increased R&D investment and a regulatory focus on animal welfare.

CNS DisordersMetabolic DiseasesToxicology

Technology Platform

Developer of the Culex® Automated Sampling Systems for hands-off fluid collection in conscious rodents and Open Flow Microperfusion (OFM) technology for superior interstitial fluid sampling of large molecules, both designed to refine animal research and improve data quality.

Opportunities

The growing emphasis on ethical animal research (3Rs) and the need for higher-quality, translational preclinical data create strong tailwinds for BASi's automation and refinement technologies.
Integration with Inotiv's full-service CRO provides a unique channel to bundle products with high-value studies, driving adoption and creating a recurring consumables revenue stream.

Risk Factors

Performance is heavily dependent on the financial and operational health of parent company Inotiv, which has faced challenges.
Market adoption of new technologies can be slow, competing against entrenched manual methods, and the business is exposed to cyclical swings in pharmaceutical R&D spending.

Competitive Landscape

BASi faces direct competition from firms like DILLER Instruments in automated sampling and Harvard Bioscience/M Dialysis in microdialysis. Its key differentiators are its superior OFM technology for macromolecule recovery, deep integration with a major CRO (Inotiv), and a strong value proposition aligned with the ethical 3Rs framework.